Summary of Product Characteristics
last updated on the eMC:
19/09/2007
|
SPC
|
Minims Tropicamide 1% w/v
|
Go to top of the pageGo to top of the page | Clear, colourless, sterile eye drops containing Tropicamide Ph. Eur. 1% w/v. | |
Go to top of the page | Single-use, sterile eye drops. | |
Go to top of the pageGo to top of the page | As a topical mydriatic and cycloplegic. | |
Go to top of the page | Adults (including the elderly): 1 drop followed by a second drop after an interval of 5 minutes. A further 1 drop may be instilled after 30 minutes, if required.Children: At the discretion of the physician. | |
Go to top of the page | Do not use in patients with a known hypersensitivity to tropicamide. Tropicamide is contraindicated in narrow angle glaucoma and in eyes where the filtration angle is narrow, as an acute attack of angle closure glaucoma may be precipitated. | |
Go to top of the page | Use with caution in an inflamed eye, as hyperaemia greatly increases the rate of systemic absorption through the conjunctiva. Care should be exercised in small children. Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following the instillation of the drops. (This blocks the passage of drops via the naso-lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa. It is especially advisable in children.) | |
Go to top of the pageGo to top of the page | There is no evidence as to the drug's safety in human pregnancy, nor is there evidence from animal work that it is free from hazard. This product should only be used in pregnancy if considered essential by the physician | |
Go to top of the page | Patient warning: Patients who receive a mydriatic may suffer from photophobia and this may impair their ability to drive under certain circumstances. | |
Go to top of the page | Transient stinging, dry mouth and blurred vision may occur following the use of this product. | |
Go to top of the page | Systemic effects from Minims Tropicamide are not expected. Should an overdose occur causing local effects, e.g. sustained mydriasis, pilocarpine or 0.25% w/v physostigmine should be applied. | |
Go to top of the pageGo to top of the page | Tropicamide is a parasympatholytic agent, which acts by blocking the action of the parasympathetic nervous system. As acetylcholine is the neuro-humoral transmitter at the receptor site of the parasympathetic nervous system, tropicamide competes with acetylcholine for uptake at the receptor sites, thereby blocking its action. The results are mydriasis, due to unopposed action of the dilator pupillae, and cycloplegia. | |
Go to top of the page | No data on the pharmacokinetics of topical tropicamide are available. | |
Go to top of the page | There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC. | |
Go to top of the pageGo to top of the page | Sodium hydroxide Hydrochloric acid Purified water | |
Go to top of the pageGo to top of the pageGo to top of the page | Store below 25ºC. Do not freeze. Protect from light. | |
Go to top of the page | A sealed, conical shaped container fitted with a twist and pull-off cap. Each Minims unit is overwrapped in an individual polypropylene/paper pouch. Each container holds approximately 0.5ml of solution. | |
Go to top of the page | Each Minims unit should be discarded after a single use. | |
Go to top of the page | Chauvin Pharmaceuticals Ltd 106 London Road Kingston-upon-Thames Surrey KT2 6TN England | |
Go to top of the page | PL 0033/0078 Legal category: POM | |
Go to top of the page | Date of first Authorisation: 10.7.79 | |
Go to top of the page
More information about this product
Link to this document from your website: http://emc.medicines.org.uk/medicine/6038/SPC/Minims Tropicamide 1% w/v/